NOCLINCAL EVALUATION FOR ANTICANCER PHARMACEUTICALS 9

This Guideline has been developed by the appropriate ICH Expert Working Group and has been subject to consultation by the regulatory parties .In accordance with the ICH Process . At Step 4 of the Process the final draft is recommended for adoption to the regulatory bodies of the European Union , Japan and USA .